Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.54 USD | +7.63% | +12.89% | +30.93% |
05-06 | Sector Update: Health Care Stocks Higher in Late Afternoon Trading | MT |
05-06 | Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.93% | 648M | C | ||
+9.15% | 106B | B+ | ||
-1.08% | 104B | B+ | ||
+6.14% | 23.25B | B | ||
-11.55% | 22.5B | B+ | ||
-7.01% | 18.7B | A- | ||
-37.08% | 17.95B | A- | ||
-9.91% | 16.99B | B | ||
+7.55% | 14.26B | C+ | ||
+40.04% | 12.76B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LYEL Stock
- Ratings Lyell Immunopharma, Inc.